KemPharm (KMPH) IPO Opens Up 7%

Today's IPO for KemPharm (NASDAQ: KMPH) opened for trading at $11.75 after pricing 5,090,909 shares of its common stock at a price to the public of $11.00 per share.

Cowen and Company and RBC Capital Markets are acting as joint book-running managers for the offering. Canaccord Genuity and Oppenheimer & Co. are acting as co-managers.

KemPharm is a specialty pharmaceutical company focused on the discovery and development of NME prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high needs areas of pain, ADHD and other CNS disorders.

You May Also Be Interested In

• CopperTech Metals launches IPO roadshow on NYSE at $16-$18 per share
• Sinda Ltd. files for IPO on NYSE, targeting up to $13.25 per share
• First Carolina Financial Services lists on NYSE under ticker FCBM